KNOXVILLE, TN, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that results from a meta-analysis of response, survival, and safety data from the Company’s Phase 2 and 3 clinical trials (NCT00521053 and NCT02288897, respectively) and expanded access program (EAP) (NCT01260779) of single-agent cancer immunotherapy PV-10 (rose bengal disodium) for the treatment of Stage III cutaneous melanoma was presented at the SMR 2021 Virtual Congress (the Society for Melanoma Research annual meeting), which was held online from October 28th to 31st.
Time-to-response (TTR): median 2.4 months, mean 2.6, range 0.7-12
Time-to-progression (TTP): median not reached
Time-to-treatment failure (TTF): median not reached
Survival (184 patients)
Overall survival (OS): median 44.9 months
Disease-specific survival (DSS): median 53.8 months[/list
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “For a Stage III cutaneous melanoma patient population with unique locoregional disease characteristics having a serious condition and facing an unmet medical need, these PV-10 data unequivocally display a positive risk-benefit profile: rapid response to PV-10 treatment, a high injected-lesion complete response rate, and an attractive safety profile.”
Mr. Rodrigues added, “This meta-analysis represents approximately 12 years, 185 patients, and 1,200 lesions worth of PV-10 data. The results categorically quantify a robust response of Stage III melanoma lesions to intralesional PV-10 treatment that is temporally consistent and reproducible across multiple different countries, sites, principal investigators, and study protocols. The data compare very favorably with those reported for drug products approved for Stage III melanoma, such as oncolytic virus and immune checkpoint blockade therapies.”
Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days. This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB). In CB-refractory advanced cutaneous melanoma, PV-10 may restore disease-specific T cell function. IL PV-10 has been administered to over 450 patients with cancers of the skin and of the liver. It is administered under visual, tactile, or ultrasound guidance to superficial malignancies, and under CT or ultrasound guidance to visceral hepatic tumors. IL PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma).
Systemic administration of PV-10 is undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, and as a treatment for relapsed and refractory blood cancers.
Different formulations and routes of administration of PV-10 and rose bengal disodium are also undergoing clinical and/or preclinical study in virology, microbiology, ophthalmology, dermatology, and animal health.
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on an entire and wholly-owned family of small molecules called halogenated xanthenes. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at https://www.provectusbio.com.
PV-10® is registered trademark of Provectus Pharmatech, Knoxville, Tennessee, U.S.A.
The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.